Fady Ghali, MD
Urology · New Haven, CTNPI 1992156640
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $6,975 of the $9,917 with a category attached, or 70.3%. 9 manufacturers reported payments, led by Ferring Pharmaceuticals Inc. at 42.2% of the total.
Across 23 payments — averaging $431.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ferring Pharmaceuticals Inc.$4K
- Urogen Pharma, Inc.$4K
- Ferring Pharmaceuticals AS$2K
- Boston Scientific$248
- Johnson & Johnson$128
- Astellas Pharma US Inc$79
- plus $126 from 3 others
What the payments were for
- Speaking & faculty fees$6,97570%
- Travel & lodging$1,23112%
- Food & beverage$1,71117%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ferring Pharmaceuticals Inc. | 5 | $4,183 |
| Urogen Pharma, Inc. | 7 | $3,611 |
| Ferring Pharmaceuticals AS | 4 | $1,542 |
| Boston Scientific | 2 | $248 |
| Johnson & Johnson | 1 | $128 |
| Astellas Pharma US Inc | 1 | $79 |
| Medtronic | 1 | $59 |
| Myriad Genetic Laboratories, Inc. | 1 | $48 |
| Seagen Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ADSTILADRIN$5,523
- JELMYTO$3,394
- LITHOCLAST$139
- Erleada$128
- REZUM$109
How this compares
$9,917 in reported general payments places this provider in the 80th percentile of 156 urology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 25 | $14,886 |
| Tamsulosin Hcl | 62 | $752 |
| Oxybutynin Chloride ErOxybutynin Chloride | 22 | $520 |
| Finasteride | 26 | $330 |
| NitrofurantoinNitrofurantoin Macrocrystal | 13 | $252 |
| Oxybutynin Chloride | 16 | $119 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $79 | $14,88625 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 156 urology providers in Connecticut.
Other urology in New Haven
- Daniel KellnerNew Haven$122K
- Preston SprenkleNew Haven$57K
- Stanton HonigNew Haven$40K
- Michael LeapmanNew Haven$21K
- Jason LeeNew Haven$19K
- Leslie RickeyNew Haven$17K
- Gregory LacyNew Haven$11K
- Guy ManettiNew Haven$7K
- Wei Shen TanNew Haven$6K
- Ganesh SanekommuNew Haven$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.